Updates on the Use of Biosimilars for the Treatment of Inflammatory Bowel Disease

被引：0
|
作者：
Velayos, Fernando [1 ]
机构：
[1] Kaiser Permanente Med Grp, Div Gastroenterol & Hepatol, San Francisco, CA 94115 USA
来源：
PRACTICAL GASTROENTEROLOGY | 2022年 / 46卷 / 07期
关键词：
DOUBLE-BLIND; INFLIXIMAB; COHORT; SAFETY;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Biologic therapy with monoclonal antibodies has been an effective strategy for improving outcomes in patients with inflammatory bowel disease. These therapies remain expensive. Over the past several years, biosimilars have entered the marketplace in the United States with the promise of reducing costs. Biosimilar's are biological products that are similar but not identical to the original biologic agent. This review discusses several aspects of biosimilars, including how they are approved as well as the latest data supporting their use in inflammatory bowel disease.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Insights on the use of biosimilars in the treatment of inflammatory bowel disease
    Michael K Zheng
    David Q Shih
    Gary C Chen
    [J]. World Journal of Gastroenterology, 2017, (11) : 1932 - 1943
  • [2] Insights on the use of biosimilars in the treatment of inflammatory bowel disease
    Zheng, Michael K.
    Shih, David Q.
    Chen, Gary C.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (11) : 1932 - 1943
  • [3] Biosimilars for the Treatment of Inflammatory Bowel Disease
    Rudrapatna, Vivek A.
    Velayos, Fernando
    [J]. PRACTICAL GASTROENTEROLOGY, 2019, 43 (04) : 84 - 91
  • [4] The use of biosimilars in paediatric inflammatory bowel disease
    Jongsma, Maria Myrthe Elisabeth
    Vulto, Arnold
    de Ridder, Lissy
    [J]. CURRENT OPINION IN PEDIATRICS, 2017, 29 (05) : 560 - 565
  • [5] Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
    Annese, Vito
    Vecchi, Maurizio
    [J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 (11) : 963 - 968
  • [6] Position statement on the use of biosimilars in inflammatory bowel disease
    Emanuel, Burri
    Pascal, Juillerat
    Michel, Maillard H.
    Michael, Manz
    Pierre, Michetti
    Christian, Mottet
    Gerhard, Rogler
    Nadine, Zahnd
    Stephan, Vavricka
    [J]. SWISS MEDICAL WEEKLY, 2019, 149
  • [7] Biosimilars in inflammatory bowel disease
    Siegmund, B.
    Atreya, R.
    Bokemeyer, B.
    Kruis, W.
    Mudter, J.
    Sander, C.
    Schreiber, S.
    Reindl, W.
    Zeissig, S.
    Kucharzik, T.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (11): : 1217 - 1222
  • [8] Biosimilars in Inflammatory Bowel Disease
    Buchner, Anna M.
    Schneider, Yecheskel
    Lichtenstein, Gary R.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (01): : 45 - 56
  • [9] Biosimilars in inflammatory bowel disease
    Talathi, Saurabh
    Baig, Kondal R. Kyanam Kabir
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2020, 21 (11) : 610 - 620
  • [10] Biosimilars in inflammatory bowel disease
    Gargallo, Carla J.
    Lue, Alberto
    Gomollon, Fernando
    [J]. MINERVA MEDICA, 2017, 108 (03) : 239 - 254
12345